Floatz logo

Mirdametinib

Solid Carcinoma

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Solid Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Academic and Community Cancer Research United
Phase 2B
Trifluridine
Academic and Community Cancer Research United
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1/2B
Palbociclib
Academic and Community Cancer Research United
Phase 2B
Binimetinib
Academic and Community Cancer Research United
Phase 2B

View all 50 →

Same molecule, other indications

Mirdametinib is also rated in:

melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →